Comparing kanuka oil and hydrocortisone cream for treating atopic dermatitis
Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in the Treatment of Patients With Mild Atopic Dermatitis
This study tests whether 3% kanuka oil can help people with atopic dermatitis feel less itchy and improve their skin better than 1% hydrocortisone cream.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 12 Years to 75 Years |
| Sex | All |
| Sponsor | Nexgen Dermatologics, Inc. Industry-sponsored |
| Locations | 1 site (Boynton Beach, Florida) |
| Trial ID | NCT06488742 on ClinicalTrials.gov |
What this trial studies
This study investigates the efficacy of 3% kanuka oil compared to 1% hydrocortisone cream in patients suffering from atopic dermatitis. The focus is on alleviating pruritus, a common and distressing symptom associated with this condition. Participants will be assessed based on their itch severity and overall skin condition to determine which treatment provides better relief. The study aims to explore alternative, natural treatment options for patients who have not found sufficient relief from conventional therapies.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 12 years and older who have been diagnosed with atopic dermatitis for more than two years and experience significant itching.
Not a fit: Patients currently using topical or systemic corticosteroids or other non-emollient therapies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a natural and effective treatment option for patients with atopic dermatitis, potentially improving their quality of life.
How similar studies have performed: While there are various treatments for atopic dermatitis, the use of kanuka oil is relatively novel, and this study aims to explore its effectiveness compared to a standard treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age greater than 12 years, diagnosis of atopic dermatitis for longer than 2 years, investigator's static global assessment score of either 2 or 3, and initial worst itch numerical rating scale (WI-NRS) for itch greater than 4. Exclusion Criteria: * the use of topical or systemic corticosteroids within 28 days of entering the study, the use of any other non-emollient therapy within 28 days of entering the study,nursing, and pregnancy
Where this trial is running
Boynton Beach, Florida
- Berlin Center — Boynton Beach, Florida, United States (Recruiting)
Study contacts
- Study coordinator: Joshua Berlin, MD
- Email: joshberlin@hotmail.com
- Phone: 561-729-5252
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.